Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells

Stem Cells and Development

Volumn 21, Issue 16, 2012, Pages 2926-2938

  Lehmann, Dorit ^a   Spanholtz, Jan ^b   Osl, Markus ^a   Tordoir, Marleen ^b   Lipnik, Karoline ^a   Bilban, Martin ^a   Schlechta, Bernhard ^c   Dolstra, Harry ^b   Hofer, Erhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD56 ANTIGEN; COMPLEMENTARY DNA; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2A; STEM CELL FACTOR; THROMBOPOIETIN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; BIOLOGICAL MARKERS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MONOCYTES; PHENOTYPE; RECEPTORS, NATURAL KILLER CELL; STEM CELLS; TIME FACTORS; UP-REGULATION;

EID: 84867829266     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0659     Document Type: Article

References (42)

1. Di Santo JP. (2008). Natural killer cells: diversity in search of a niche. Nat Immunol 9:473-475.
2. Vivier E, JA Nunes and F Vely. (2004). Natural killer cell signaling pathways. Science 306:1517-1519.
3. Vivier E, DH Raulet, A Moretta, MA Caligiuri, L Zitvogel, LL Lanier, WM Yokoyama and S Ugolini. (2011). Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49.
4. Cooper MA, TAFehniger andMACaligiuri. (2001). The biology of human natural killer-cell subsets. Trends Immunol 22:633-640.
5. De Maria A, F Bozzano, C Cantoni and L Moretta. (2011). Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16 + NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A 108:728-732.
6. Romagnani C, K Juelke, M Falco, B Morandi, A D'Agostino, R Costa, G Ratto, G Forte, P Carrega, et al. (2007). CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178:4947-4955.
7. Ljunggren HG and KJ Malmberg. (2007). Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329-339.
8. Sutlu T and E Alici. (2009). Natural killer cell-based immunotherapy in cancer: Current insights and future prospects. J Intern Med 266:154-181.
9. Spanholtz J, M Tordoir, D Eissens, F Preijers, A van derMeer, I Joosten, N Schaap, TM de Witte and H Dolstra. (2010). High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 5:e9221.
10. Spanholtz J, F Preijers, M Tordoir, C Trilsbeek, J Paardekooper, T de Witte, N Schaap and H Dolstra. (2011). Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 6:e20740.
11. NK cells as post consolidation therapie in AML: www.trialregister.nl/ trialreg/admin/rctview.asp?TC=2818
12. HOVON-associated PLMA25 NK-cell study: www.hovon .nl/studies/studies-per- ziektebeeld/sct.html?action=show studie&studie-id=87&categorie-id=11
13. Brostjan C, T Bellon, Y Sobanov, M Lopez-Botet and E Hofer. (2002). Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. J Immunol Methods 264:109-119.
14. Bilban M, N Ghaffari-Tabrizi, E Hintermann, S Bauer, S Molzer, C Zoratti, R Malli, A Sharabi, U Hiden, et al. (2004). Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 117:1319-1328.
15. Bilban M, D Heintel, T Scharl, T Woelfel, MM Auer, E Porpaczy, B Kainz, A Krober, VJ Carey, et al. (2006). Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 20:1080-1088.
16. Blomberg K, C Granberg, I Hemmila and T Lovgren. (1986). Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods 86:225-229.
17. Grzywacz B, N Kataria, M Sikora, RA Oostendorp, EA Dzierzak, BR Blazar, JS Miller and MR Verneris. (2006). Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108:3824-3833.
18. Sivakumar PV, A Gunturi, M Salcedo, JD Schatzle, WC Lai, Z Kurepa, L Pitcher, MS Seaman, FA Lemonnier, et al. (1999). Cutting edge: Expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1 + Ly-49- cells: A possible mechanism of tolerance during NK cell development. J Immunol 162:6976-6980.
19. Keating GM. (2010). Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445-1476.
20. Curti A, L Ruggeri, A D'Addio, A Bontadini, E Dan, MR Motta, S Trabanelli, V Giudice, E Urbani, et al. (2011). Successful transfer of alloreactive haploidentical KIR ligandmismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118:3273-3279.
21. Ruggeri L, M Capanni, E Urbani, K Perruccio, WD Shlomchik, A Tosti, S Posati, D Rogaia, F Frassoni, et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100.
22. Kim S, K Iizuka, HS Kang, A Dokun, AR French, S Greco and WM Yokoyama. (2002). In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 3:523-528.
23. Puzanov IJ, M Bennett and V Kumar. (1996). IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol 157:4282-4285.
24. Haller O, R Kiessling, A Orn and H Wigzell. (1977). Generation of natural killer cells: An autonomous function of the bone marrow. J Exp Med 145:1411-1416.
25. Miller JS, KA Alley and P McGlave. (1994). Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34 + 7 + NK progenitor. Blood 83:2594-2601.
26. Mrozek E, P Anderson and MA Caligiuri. (1996). Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34 + hematopoietic progenitor cells. Blood 87:2632-2640.
27. Huntington ND, CA Vosshenrich and JP Di Santo. (2007). Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7:703-714.
28. Strowig T, O Chijioke, P Carrega, F Arrey, S Meixlsperger, PC Ramer, G Ferlazzo and C Munz. (2010). Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 116:4158-4167.
29. Freud AG, A Yokohama, B Becknell, MT Lee, HC Mao, AK Ferketich and MA Caligiuri. (2006). Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203:1033-1043.
30. Grzywacz B, N Kataria, BR Blazar, JS Miller and MR Verneris. (2010). Natural killer-cell differentiation by myeloid progenitors. Blood 117:3548-3558.
31. Clarkson SB and PA Ory. (1988). CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes. J Exp Med 167:408-420.
32. Elpek KG, MP Rubinstein, A Bellemare-Pelletier, AW Goldrath and SJ Turley. (2010). Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A 107:21647-21652.
33. Huntington ND, N Legrand, NL Alves, B Jaron, K Weijer, A Plet, E Corcuff, E Mortier, Y Jacques, H Spits and JP Di Santo. (2009). IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206: 25-34.
34. Soderquest K, N Powell, C Luci, N van Rooijen, A Hidalgo, F Geissmann, T Walzer, GM Lord and A Martin-Fontecha. (2011). Monocytes control natural killer cell differentiation to effector phenotypes. Blood 117:4511-4518.
35. Lopez-Botet M, T Bellon, M Llano, F Navarro, P Garcia and M de Miguel. (2000). Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61:7-17.
36. Guma M, C Cabrera, I Erkizia, M Bofill, B Clotet, L Ruiz and M Lopez-Botet. (2006). Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 194:38-41.
37. Cooley S, F Xiao, M Pitt, M Gleason, V McCullar, TL Bergemann, KL McQueen, LA Guethlein, P Parham and JS Miller. (2007). A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110:578-586.
38. Wendt K, E Wilk, S Buyny, J Buer, RE Schmidt and R Jacobs. (2006). Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol 80:1529-1541.
39. Hanna J, P Bechtel, Y Zhai, F Youssef, K McLachlan and O Mandelboim. (2004). Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 173:6547-6563.
40. Bhat R and C Watzl. (2007). Serial killing of tumor cells by human natural killer cells - enhancement by therapeutic antibodies. PLoS One 2
41. Rubnitz JE, H Inaba, RC Ribeiro, S Pounds, B Rooney, T Bell, CH Pui and W Leung. (2010). NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:955-959.
42. Miller JS, Y Soignier, A Panoskaltsis-Mortari, SA McNearney, GH Yun, SK Fautsch, D McKenna, C Le, TE Defor, et al. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057.